2016 American Transplant Congress » Poster Session D: Viral Hepatitis

6:00pm-7:00pm

Clinical, Histologic and Charge Endpoints When Populations with Hepatitis C Recurrence Are Treated with Direct-Acting Antiviral or Interferon Based Therapies.

S. Olson, A. McCann, S. Kumer, T. Schmitt, B. Floyd, R. Taylor, R. Gilroy.

6:00pm-7:00pm

Direct-Acting Antivirals for Hepatitis C Treatment in Kidney Transplant Recipients.

N. Goyal, W. Huepfel, A. Tierney, N. Issa, J. Lake, J. Thompson, M. Hassan, H. Ibrahim, A. Kukla.

6:00pm-7:00pm

Evaluation of Long Term Outcome After Living Donor Liver Transplantation in Sequential 653 Recipients with or without Viral Infection: Is HBV & HCV Co-Infection Better Than the Monoinfection? A Single Center Retrospective Analysis.

H. Yang, A. Thorat, L. Jeng, C.-C. Yeh, T.-H. Chen, S.-C. Hsu, K.-S. Poon.

6:00pm-7:00pm

Hepatitis B Immune Globulin Withdrawal in HBsAg Positive Liver Transplant Patients.

A. Nolan,¹ C. Onwudiwe,¹ A. Rangnekar,² R. Satoskar,² T. Fishbein.²

6:00pm-7:00pm

Hepatitis C Eradication with Sofosbuvir Based Regimens Leads to Significant Metabolic Changes in Post Orthotopic Liver Transplant Patients.

A. Morales,¹ M. Singla,² H. Greenwald,¹ S. Robertazzi,¹ C. Rodigas,¹ V. Washington,¹ R. Satoskar,¹ C. Smith.¹

6:00pm-7:00pm

Initial Experience with Ledipasvir-Sofosbuvir Based Therapy for Recurrent Hepatitis C After Liver Transplantation.

A. Weick, O. Sadiq, S.-M. Jafri, D. Moonka.

6:00pm-7:00pm

Is SVR Associated with Improved Hepatic Function in Hepatitis C Gen 1 Pts with Cirrhosis 1 Year After Completing Treatment with Sofosbuvir + Simeprevir +/- Ribavirin?

A. Modi,¹ J. Hermann,¹ H. Nazario,² S. Gonzalez,¹ J. Gripshover,³ M. Gautam,¹ J. Weinstein,² D. Potosky,³ M. Barnes,² A. Habib,² P. Mantry,² J. Trotter.¹

6:00pm-7:00pm

Limited Hepatitis B Immune Globulin Following Liver Transplant for Hepatitis B.

T. Sievers, J. Thompson, J. Lake.

6:00pm-7:00pm

Outcomes of Ribavirin Free Treatment of Recurrent Genotype 1 , Hepatitis C Infection Post Liver Transplant.

D. Jones,¹ S. Baggett,¹ M. Shoreibah,² O. Massoud.²

6:00pm-7:00pm

Safety and Efficacy of Ledipasvir/Sofosbuvir (LS) with or without Ribavirin (RBV) for Treatment of Recurrent Hepatitis C Infection Post-Liver Transplant.

K. Gutierrez, J. Scheuermann, I. Goldvarg, S. Joshi, G. Tyson, N. Bzowej, N. Girgrah, S. Anders, G. Loss, G. Therapondos.

6:00pm-7:00pm

Sofosbuvir-Based Regimen in Treatment Experienced-Post Liver Transplant Patients with Hepatitis C Recurrence.

A. Ajlan,¹ A. Aljedai,¹ H. Elsiesy,² D. Alkortas,¹ R. Alarieh,² W. Alhumodi,² D. Broring,² M. Alsebayel,² F. Aba Alkhail.²

6:00pm-7:00pm

Tacrolimus Levels in Patients Treated with Direct Acting Antivirals Post-Transplant.

J. Wiegel, T. Egbuka.

6:00pm-7:00pm

Virological Response at 4 Weeks With a Sofosbuvir-Based Antiviral Regimen in Liver Transplant Recipients with Recurrent Hepatitis C.

T. Pastrana-Camacho,¹ M. Bradley,¹ H. Winters,¹ S. Black,² K. Porter,³ K. Mumtaz.⁴